Data / Drug companies / Cyclosporine
Cyclosporine: 24 companies and 48 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Cyclosporine is listed in the FDA National Drug Code Directory by 24 companies, with 48 products in commercial distribution. 32 of the products (66.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, liquid filled; emulsion; capsule, gelatin coated, and the newest product started marketing on September 21, 2026.
The request: Get every company that lists cyclosporine in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 24
- Products
- 48
- Generic (ANDA) products
- 32 (66.7%)
- Application numbers
- 22
- Routes
- Oral, Ophthalmic, Topical, Intravenous
- Brand names
- Neoral, Sandimmune, Gengraf, Cequa, Restasis, Verkazia, Restasis MultiDose
- openFDA record search
- api.fda.gov
Companies that list cyclosporine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Apotex Corp. | 6 | capsule, liquid filled; capsule, gelatin coated | Generic drugs (ANDA) | February 7, 2022 |
| Novartis Pharmaceuticals Corporation | 6 | capsule, liquid filled; injection | New drug applications (NDA) | July 14, 1995 |
| Aurobindo Pharma Limited | 3 | capsule, liquid filled | Generic drugs (ANDA) | September 17, 2026 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 3 | capsule, liquid filled | Generic drugs (ANDA) | November 30, 2022 |
| Strides Pharma Science Limited | 3 | capsule, liquid filled | Generic drugs (ANDA) | August 16, 2022 |
| Teva Pharmaceuticals USA, Inc. | 3 | capsule, liquid filled | Generic drugs (ANDA) | June 8, 2021 |
| AbbVie Inc. | 2 | capsule | Generic drugs (ANDA) | November 1, 2015 |
| Allergan, Inc. | 2 | emulsion | New drug applications (NDA) | November 10, 2016 |
| American Health Packaging | 2 | capsule, gelatin coated | Generic drugs (ANDA) | November 3, 2015 |
| Dr. Reddy's Laboratories Inc. | 2 | capsule, liquid filled | Generic drugs (ANDA) | July 1, 2024 |
| Qilu Pharmaceutical Co., Ltd. | 2 | capsule, liquid filled | Generic drugs (ANDA) | September 15, 2025 |
| Sun Pharmaceutical Industries, Inc. | 2 | solution/ drops | New drug applications (NDA) | August 15, 2018 |
| A-S Medication Solutions | 1 | emulsion | New drug applications (NDA) | April 1, 2003 |
| Cipla USA Inc. | 1 | emulsion | Generic drugs (ANDA) | September 21, 2026 |
| Devatis, Inc. | 1 | emulsion | Generic drugs (ANDA) | July 4, 2024 |
| Harrow Eye, LLC | 1 | emulsion | New drug applications (NDA) | February 1, 2022 |
| KVK-Tech, Inc. | 1 | emulsion | Authorized generics (NDA) | February 10, 2022 |
| Lupin Pharmaceuticals, Inc. | 1 | emulsion | Authorized generics (NDA) | May 11, 2022 |
| Mylan Pharmaceuticals Inc. | 1 | emulsion | Generic drugs (ANDA) | February 3, 2022 |
| Santen Incorporated | 1 | emulsion | New drug applications (NDA) | February 1, 2022 |
| Saptalis Pharmaceuticals, LLC. | 1 | emulsion | Generic drugs (ANDA) | December 12, 2025 |
| Teva Pharmaceuticals USA, Inc. | 1 | solution | Generic drugs (ANDA) | March 29, 2005 |
| Teva Pharmaceuticals, Inc. | 1 | emulsion | Generic drugs (ANDA) | October 28, 2025 |
| Upsher-Smith Laboratories, LLC | 1 | emulsion | Generic drugs (ANDA) | March 27, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, liquid filled | 23 | 47.9% |
| Emulsion | 14 | 29.2% |
| Capsule, gelatin coated | 4 | 8.3% |
| Capsule | 2 | 4.2% |
| Solution/ drops | 2 | 4.2% |
| Solution | 2 | 4.2% |
| Injection | 1 | 2.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 32 | 66.7% |
| New drug applications (NDA) | 13 | 27.1% |
| Authorized generics (NDA) | 3 | 6.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Calcineurin Inhibitor Immunosuppressant | 48 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.